ClinicalTrials.gg
CompletedNCT07753434Updated Aug 7, 2026

Intraoperative Laser Speckle Imaging Predicts Early Renal Function After Kidney Transplantation

An observational study in Postoperative Renal Function, sponsored by The Second Affiliated Hospital of Chongqing Medical University. Completed at 1 site in China. Per ClinicalTrials.gov, last updated 2026-08-07.

Sponsored by The Second Affiliated Hospital of Chongqing Medical University · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
80
Sex
All
01

Study summary

This observational study aims to explore the predictive value of intraoperative laser speckle contrast imaging for early postoperative renal function in kidney transplant recipients. The core research question is: What is the efficacy of intraoperative laser speckle contrast imaging in predicting early postoperative renal function among kidney transplant patients? This study will enroll kidney transplant patients who undergo intraoperative laser speckle contrast imaging and collect relevant evaluation data.

Last updated on February 27, 2025

02

Conditions studied

  • Postoperative Renal Function

Keywords

  • postoperative renal function
  • laser speckle contrast imaging
03

In context

Lead sponsor

The Second Affiliated Hospital of Chongqing Medical University is the lead sponsor of 103 studies on the registry; 33 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients who underwent renal transplantation at our hospital between August 2024 and February 2025.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients undergoing renal transplantation in our hospital.

Exclusion criteria

Exclusion Criteria:

  • Patients who need reoperation within 7 days after initial renal transplantation.
  • Patients with acute rejection within 24 hours after operation.
05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
80 participants (actual)
Patient registry
No

Interventions

  • Devicelaser speckle contrast imaging (LSCI)

    Before abdominal closure, renal microcirculation was assessed using the RFLSI-ZW laser speckle contrast imaging (LSCI) system (RWD Life Science) which was mounted on a portable stand. The device was positioned 15-30 cm above the transplanted kidney, with the speckle lens aligned to the graft surface. Automatic focusing was applied to optimize image clarity, and images of the upper pole of the kidney were captured within a 15 × 15 cm field of view. 60 seconds of microcirculation imaging and perfusion curves were recorded at the upper pole of the kidney after reperfusion and immediately prior to abdominal closure (Figure 1). Perfusion Index (PI) was calculated using the software of the RFLSI-ZW LSCI system, which was closely related to the product of mean erythrocyte flow velocity and concentration within the tissue.

06

What researchers measure

Primary outcomes

  1. Slow graft function (SGF)

    Time frame: Within 7 days after renal transplantation

Secondary outcomes

  1. Postoperative Cr

    Time frame: Within the first 7 postoperative days

  2. Postoperative BUN

    Time frame: Within the first 7 postoperative days

  3. Postoperative UO

    Time frame: Within the first 7 postoperative days

  4. Postoperative eGFR

    Time frame: Within the first 7 postoperative days

  5. Hospital length of stay

    The total length of hospital stay after renal transplantation.

    Time frame: Up to 12 weeks

07

Study locations

1 site
  • The Second Affiliated Hospital of Chongqing Medical University
    Chongqing, Chongqing Municipality 400010, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2024 to primary completion in Feb 2025, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 1, 2026
First posted
Aug 7, 2026
StartActual
Aug 1, 2024
Primary completionActual
Feb 1, 2025
CompletionActual
Feb 27, 2025
Last update
Aug 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07753434
Responsible party
Guangyou Duan (professor, The Second Affiliated Hospital of Chongqing Medical University) — Principal investigator
First posted
Aug 7, 2026
Start date
Aug 1, 2024
Primary completion
Feb 1, 2025
Completion
Feb 27, 2025
Last update
Aug 7, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion